Clinical trial · no report yet · Phase 3
NCT06435429
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- NCT06435429 ↗
- Recruiting
- Jazz Pharmaceuticals
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 1 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Metastatic HER2-positive Breast Cancer
- Interventions
- Zanidatamab; Trastuzumab; Eribulin; Vinorelbine; Gemcitabine; Capecitabine
- Arms
- Zanidatamab plus physician's choice of chemotherapy · Experimental
- Trastuzumab plus physician's choice of chemotherapy · Active comparator
- Enrollment
- 550 (estimated)
- Primary outcomes
- Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)
- Sponsor
- Jazz Pharmaceuticals
- Start
- Aug 13, 2024
- Primary completion
- Apr 28, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06435429 · updated Feb 10, 2026